MS4A3 (Membrane Spanning 4-Domains A3), also known as HTm4 (Hematopoietic Tetraspanin 4), is a member of the MS4A (Membrane-Spanning 4-Domains) family of tetraspanin proteins. The MS4A family consists of at least 13 genes clustered on chromosome 11q12, encoding proteins characterized by four transmembrane domains that form characteristic tetraspanin microdomains (TEMs) in the plasma membrane 1. MS4A3 is primarily expressed in hematopoietic cells, with lower expression in brain tissue where it may participate in immune modulation relevant to neuroinflammation and Alzheimer's Disease 2.
| MS4A3 Protein |
|---|
| Protein Name | Membrane Spanning 4-Domains A3 |
| Alternative Names | HTm4, MS4A3 |
| Gene | MS4A3 |
| UniProt ID | Q9H5Y4 |
| PDB Structures | - |
| Molecular Weight | 25-30 kDa (238 amino acids) |
| Subcellular Localization | Plasma membrane, endoplasmic reticulum |
| Protein Family | MS4A (Tetraspanin) family |
¶ Structure and Function
MS4A proteins share a characteristic tetraspanin structure 3:
Four Transmembrane Domains: The defining feature of tetraspanins is four transmembrane helices (TM1-TM4) that span the plasma membrane, creating two extracellular loops (small and large) and two intracellular loops.
Small Extracellular Loop (SEL, residues 60-90): The short extracellular loop between TM2 and TM3 participates in protein-protein interactions and may serve as a ligand-binding domain.
Large Extracellular Loop (LEL, residues 120-190): The larger extracellular loop between TM3 and TM4 contains conserved cysteine residues forming disulfide bonds and serves as the primary interaction surface for partner proteins.
N- and C-Terminal Cytoplasmic Domains: Both termini are located in the cytoplasm and contain motifs for protein sorting and signaling.
¶ Tetraspanin Microdomains (TEMs)
MS4A proteins organize into tetraspanin-enriched microdomains:
- Platform formation: Tetraspanins cluster to form membrane microdomains
- Partner recruitment: These platforms recruit specific partner proteins
- Signaling complexes: TEMs concentrate signaling molecules
- Membrane organization: Organize lipid rafts and signaling domains 4
The MS4A gene cluster on chromosome 11q12 contains multiple genes with relevance to AD:
MS4A4A: Strongly associated with AD risk. Expression in microglia influences disease progression. Serves as a genetic determinant of CSF biomarker levels.
MS4A6A: Another AD risk gene expressed in microglia. Associated with amyloid deposition and disease progression.
MS4A7 (CD20L3): Expressed in immune cells, associated with AD endophenotypes.
MS4A3: While less directly studied than MS4A4A and MS4A6A, MS4A3 may participate in similar immune functions 5.
Genome-wide association studies have identified the MS4A gene cluster as an AD risk locus:
- MS4A4A variants: Strongest associations with AD risk
- MS4A6A variants: Second major AD risk gene in this cluster
- Expression QTLs: Variants affecting MS4A expression correlate with AD traits
- Pleiotropy: The cluster influences multiple AD biomarkers 6
MS4A family genes are predominantly expressed in microglia:
- Brain expression: Highest expression in microglia compared to other cell types
- Disease association: Expression correlates with AD pathological features
- Functional studies: MS4A genes regulate microglial function
- Therapeutic targeting: Modulating MS4A may influence neuroinflammation 7
MS4A proteins regulate microglial activation:
- Inflammatory responses: MS4A modulates cytokine production
- Phagocytosis: May regulate microglial phagocytic activity
- Cell migration: Involved in microglial motility
- Neuronal support: May provide trophic support to neurons 8
MS4A expression correlates with AD biomarkers:
- CSF biomarkers: MS4A genetic variants influence Aβ42 and tau levels
- Imaging biomarkers: Association with amyloid PET load
- Clinical progression: Correlates with cognitive decline
- Therapeutic response: May predict treatment response 9
MS4A3 may play roles in demyelinating diseases:
- Immune cell function: Regulates immune cell activation
- Demyelination: May influence oligodendrocyte function
- Autoimmunity: Modulates autoimmune responses
- Therapeutic potential: Target for MS therapeutics 10
While less studied in PD, MS4A proteins may be relevant:
- Neuroinflammation: Microglial activation in PD
- Protein clearance: May affect α-synuclein clearance
- Therapeutic targeting: Potential for disease modification 11
MS4A as a therapeutic target:
- Genetic validation: GWAS evidence supports causality
- Expression studies: Brain expression supports mechanism
- Functional studies: Modulating affects disease pathways
- Safety considerations: Peripheral expression may affect immunity 12
¶ Antibody Approaches
Therapeutic antibodies targeting MS4A:
- MS4A4A antibodies: In development for AD
- Microglial targeting: Antibody-mediated microglial modulation
- Effector functions: Engineering for optimal activity
- Blood-brain barrier: Delivery challenges 13
Genetic approaches:
- AAV vectors: Targeted delivery to microglia
- siRNA/shRNA: Knockdown of risk alleles
- CRISPR editing: Correcting risk variants
- Expression modulation: Normalizing MS4A expression 14
¶ Interactions and Signaling
MS4A proteins interact with various partners:
- Integrins: Cell adhesion and migration
- Signaling kinases: Signal transduction
- Phosphatases: Regulatory functions
- Cytoskeletal proteins: Cell structure
MS4A modulates multiple pathways:
- PI3K/Akt: Cell survival signaling
- MAPK/ERK: Proliferation and differentiation
- NF-κB: Inflammatory responses
- Calcium signaling: Cellular signaling
Model systems for studying MS4A:
- Knockout mice: MS4A3 knockout available
- Transgenics: Humanized MS4A mouse models
- iPSC models: Human neuronal and glial models
- CRISPR models: Precise genetic manipulation 15
MS4A as a biomarker:
- Peripheral detection: Blood MS4A levels
- CSF measurement: Cerebrospinal fluid MS4A
- Imaging: PET tracers for MS4A
- Correlation studies: Disease stage relationships 16
Key questions remaining:
- MS4A3 specific function: What is the brain-specific role of MS4A3?
- Mechanism of action: How do MS4A proteins modulate disease?
- Therapeutic window: Safety considerations for targeting
- Combination therapy: Optimal approaches with other targets
Future clinical applications:
- Biomarker development: Validated clinical assays
- Patient stratification: Based on MS4A genotype
- Therapeutic development: Antibodies and small molecules
- Personalized medicine: Genotype-guided approaches 17